MedDataX Logo

The Indiana Myeloma Registry

NCT ID: NCT03616483

Last Updated: 2025-11-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

2500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-06-18

Study Completion Date

2028-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective, non-interventional, observational study. The purpose of this study is to collect data and bio-specimens that will support future research

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Plasma Cell Dyscrasias

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Multiple myeloma Monoclonal gammopathy of undetermined significance Plasmacytoma Smoldering multiple myeloma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

This is a non-interventional trial

This is a non-interventional trial

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female patients ≥ 18 years of age at the time of informed consent
2. Has been diagnosed with or is suspected to have one of the following:

1. Monoclonal Gammopathy of Undetermined Significance (MGUS)
2. Smoldering Multiple Myeloma
3. Multiple Myeloma
4. Bony or Soft Tissue Plasmacytoma
5. Primary Amyloidosis

Exclusion Criteria

\< 18 years of age

Have not been diagnosed with one of the following:

Monoclonal Gammopathy of Undetermined Significance (MGUS) b.Smoldering Multiple Myeloma c.Multiple Myeloma d.Bony or Soft Tissue Plasmacytoma e.Primary Amyloidosis
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Indiana University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Attaya Suvannasankha

Clinical Professor of Clinical Medicine

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Attaya Suvannasankha, MD

Role: PRINCIPAL_INVESTIGATOR

Indiana University School of Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Indiana University Simon Cancer Center

Indianapolis, Indiana, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Attaya Suvannasankha, MD

Role: CONTACT

Phone: 317-274-0843

Email: [email protected]

Nisha George, MD

Role: CONTACT

Phone: (317) 274-6635

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Attaya Suvannasankha, MD

Role: primary

Nisha George, MD

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IUSCC-0661

Identifier Type: -

Identifier Source: org_study_id